Transcriptomics Analyses of ALS Post-mortem Motor Cortex highlight alteration and potential biomarkers in the Neuropeptide Signalling pathway

Renata Kabiljo*¹, Heather Marriott*^{1,2}, Guy P Hunt^{1,2,3,4}, Abigail L Pfaff^{3,4}, Ahmad Al Khleifat², Brett Adey^{1,9}, Ashley Jones², Claire Troakes¹⁰, John P Quinn⁵, Richard J B Dobson^{1,7,8}, Sulev Koks^{3,4,\$}, Ammar Al-Chalabi^{2,6}, Alfredo Iacoangeli^{1,2,8,\$}

*R.K. and H.M. have contributed equally to the manuscript ^{\$}correspondence should be addressed to alfredo.iacoangeli@kcl.ac.uk and Sulev.Koks@murdoch.edu.au

¹Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

²Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 9NU, UK

³Perron Institute for Neurological and Translational Science, Nedlands, WA 6009, Australia

⁴ Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, WA 6150, Australia

⁵Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3BX, UK

⁶King's College Hospital, Bessemer Road, Denmark Hill, London, SE5 9RS, UK
⁷Institute of Health Informatics, University College London, London, UK

⁷Institute of Health Informatics, University College London, London, UK

8 National Institute for Health Research Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and King's College London, London, UK

9 Social Genetic and Developmental Psychiatry Centre, Memory Lane, London, SE5 8AF

 10 MRC London Neurodegenerative Diseases Brain Bank, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

Abstract

Background: Amyotrophic lateral sclerosis (ALS) is a fatal heterogeneous neurodegenerative disease
that typically leads to death from respiratory failure within two to five years. Despite the identification of several genetic risk factors, the biological processes involved in ALS pathogenesis remain poorly understood. The motor cortex is an ideal region to study dysregulated pathological processes in ALS as it is affected from the earliest stages of the disease. In this study, we investigated processes in ALS as it is affected from the earliest stages of the disease. In this study, we investigated η motor-cortex gene expression of cases and controls to gain new insight into the molecular footprint of ALS.

Methods: We performed a large case-control differential expression analysis of two independent post-mortem motor cortex bulk RNA-sequencing (RNAseq) datasets from the King's College London BrainBank (N = 171) and TargetALS (N = 132). Differentially expressed genes from both datasets were subjected to gene and pathway enrichment analysis. Genes common to both datasets were also reviewed for their involvement with known mechanisms of ALS pathogenesis to identify potential candidate genes. Finally, we performed a correlation analysis of genes implicated in potential candidate genes. Finally, we performed a correlation analysis of genes implicated in ϵ pathways enriched in both datasets with clinical outcomes such as the age of onset and survival.

Results: Differential expression analysis identified 2,290 and 402 differentially expressed genes in KCL BrainBank and TargetALS cases, respectively. Enrichment analysis revealed significant synapserelated processes in the KCL BrainBank dataset, while the TargetALS dataset carried an immune system-related signature. There were 44 differentially expressed genes which were common to both datasets, which represented previously recognised mechanisms of ALS pathogenesis, such as lipid metabolism, mitochondrial energy homeostasis and neurovascular unit dysfunction. Differentially expressed genes in both datasets were significantly enriched for the neuropeptide signalling pathway. By looking at the relationship between the expression of neuropeptides and their receptors with clinical measures, we found that in both datasets NPBWR1, TAC3 and SSTR1 correlated with age of onset, and $GNRH1$, TACR1 with survival. We provide access to gene-level correlated with age of onset, and GNRH1, TACR1 with survival. We provide access to gene-level
expression results to the breader research community through a publish available web applicat expression results to the broader research community through a publicly available web application.
Ibitias: I/slamesumlames on lial so ulit (https://alsgeexplorer.er.kcl.ac.uk).

Conclusion: This study identified motor-cortex specific pathways altered in ALS patients, potential conclusion: This study identified motor-cortex specific pathways alternative pathways alternative position fro molecular targets for therapeutic disease intervention and a set of neuropeptides and receptors for investigation as potential biomarkers.

Background

Amyotrophic lateral sclerosis (ALS) is a devastating, heterogeneous neurodegenerative disease that leads to death from neuromuscular respiratory failure within two to five years. Despite the heritability of ALS being largely unknown, the discovery of several genetic risk factors has driven the heritability of ALS being largely unknown, the discovery of several genetic risk factors has driven the discovery of the identification of multiple biological processes involved in the disease aetiology***. However, the
nathogonic mochanisms of ALS romain noorly understood. pathogenic mechanisms of ALS remain poorly understood.

The motor cortex is affected from the earliest stages of the disease and is one of the brain regions majorly affected by ALS pathology. Consequently, its disease expression signatures have been investigated to gain insight into the disease aetiology. Recent studies have reported differential expression of genes related to transcription, neurotransmission, protein synthesis and oxidative stress processes³, with extensive RNA expression alterations of neuroinflammatory and synapticstress processes", with extensive RNA expression alterations of neuroinflammatory and synaptic-
related perhapses identified at both gave and isoform layels⁴. Neuratheless, studies of this erities! related pathways identified at both gene and isoform levels*
region at the whole transgriptome lavel usually involve relati . Nevertheless, studies of this critical region at the whole-transcriptome level usually involve relatively small sample sizes and do not replicate their results in independent datasets.

To study functional changes occurring in the motor cortex of ALS patients, we have utilised two large To study functional changes occurring in the motor cortex of ALS patients, we have utilised two large independent RNAseq datasets of ALS patients and controls from the King's College London (KCL)
Preisponk (171 cubicate) a BrainBank (171 subjects) and TargetALS (234 samples from 132 subjects). By analysing the two underlying molecular footprint of ALS and use this information to propose novel hypotheses about underlying molecular footprint of ALS and use this importance in the propose novel hypotheses about disease mechanisms, potential drug targets and biomarkers.

Methods

Datasets

The KCL BrainBank RNAseq dataset^{5,6} consists of post-mortem RNAseq samples from KCL and the
Medical Research Council (MRC) London Neurodegenerative Diseases Brain Bank. Frozen human post-mortem tissue was taken from the primary motor cortex. The RNAseq protocol is outlined in post-mortem tissue was taken from the primary motor cortex. The RNAseq protocol is outlined in this enclusive the Supplementary Methods. 112 sporadic ALS cases and 59 controls were included in this analysis.

The TargetALS RNAseq dataset comes from TargetALS Human Postmortem Tissue Core and the New York Genome Centre (NYGC). We obtained the TargetALS dataset from https://www.targetals.org/ A list of the sample IDs of 243 samples (from 132 subjects, 112 ALS cases and 20 controls) used in this study is available in Supplementary Table 1. Frozen human post-mortem tissue was taken from the motor cortex (medial, lateral, and unspecified). Samples from different motor cortex regions for the same subjects were included, where available (see Supplementary Methods: TargetALS Sample the same subjects were included, where available (see Supplementary Methods: TargetALS Sample
Selection for more information on the inclusion of multiple samples per subject). Library preparation and sequencing of RNA are described in detail here <u>https://www.targetals.org/wp-</u>
content /uploads/2020/11/README 1 zipcontent/uploads/2020/11/README-1.2ip.

Bioinformatics, data processing and expression analysis

Both datasets were processed using the same pipeline, which is documented and distributed here:
https://github.com/rkabiljo/RNASeq_Genes_ERVs._The pipeline involves interleaving the paired https://github.com/rkabiljo/RNASeq_Genes_ERVs. The pipeline involves interleaving the paired reads using reformat.sh from BBtools' and trimming adapters and low-quality reads using bbduk.sh',
hefers aliming to the Us28 reference general using STAD⁸ Transcripts are then augustified, using before aligning to the Hg38 reference genome using $STAR⁸$. Transcripts are then quantified using .Transcripts are then quantified using HTSeq°
¤•••• . The Supplementary Methods provides more details about each one of the supplementary Methods Γ parameters used. DESeq2*° was used for normalisation and differential expression analysis. The
cerints are available at https://sithub.com/skabilis/DifferentialExpression. Cones. To test whothe scripts are available at <u>https://github.com/rkabiljo/DifferentialExpression_Genes</u>. To test whether
the number of differentially expressed genes identified in our analysis was due to chance, we performed 1,000 random permutations of case/control labels and performed differential expression analysis on each permutation. For each permutation, we counted the number of genes with false discovery rate (FDR) adjusted p-value lower than our selected cut-off of 0.05. The random permutation scripts are available here https://github.com/rkabiljo/ShufflingLabelsForDE. Functional enrichment was performed using MetaCore[™] (available at https://portal.genego.com) for Gene Ontology (GO) processes, Pathway Maps, Process Networks and Disease by Biomarker enrichments, Ontology (GO) processes, Pathway Maps, Process Networks and Disease by Biomarker enrichments,
which a Dunfilm of the used for Beether a¹² enrichment. We used DDFTICFA¹³ to derive sell whilst gProfiler2** was used for Reactome** enrichment. We used BRETIGEA** to derive cell
proportions for the following cell types: astrogytes, andethelial cells, misroglia, nourans. proportions for the following cell types; astrocytes, endothelial cells, microglia, neurons, oligodendrocytes, and oligodendrocyte progenitor cells (OPCs).

To share the results which the wider community, we developed a web application using the R α shiny α framework (version 1.7.1) to allow quick visualisation of specific gene expression in ALS cases and controls, available at https://alsgeexplorer.er.kcl.ac.uk.

Results

Sample Characteristics

The summary characteristics of the two datasets are shown in Table 1. The KCL BrainBank dataset
had significant differences between cases and controls in terms of age, RNA integrity number (RIN) and post-mortem delay (PMD). The TargetALS dataset showed no significant differences in age, sex, and RIN between cases and controls, but did display a significant difference in PMD (p-value = 0.0086). We have accounted for these differences through our choice of covariates included in the differential expression analyses (see Supplementary Methods). Principal component analysis (PCA) differential expression analyses (see Supplementary Methods). Principal component analysis (PCA) component analysis (PCA) component and $\mathcal{L}(\mathcal{L})$ plots of samples based on expression data using the 500 most variable genes are in Supplementary Figures 1A (KCL BrainBank) and 1B (TargetALS).

Table 1. KCL BrainBank and TargetALS sample characteristics. Age: Age at death. PMD: POst-mortem delay.
RIN: RNA integrity number *n-value of Chi-cquare test for categorical variables (Sev) and T-test for continue RIN: RNA integrity number. *p-value of Chi-square test for categorical variables (Sex) and T-test for continuous variables (Age, RIN Number, PMD)

Differential expression analysis identifies genes linked to ALS pathogenesis shared in both datasets

KCL BrainBank

A total of 2,290 genes were differentially expressed with an adjusted p-value of <0.05, in the KCL
BrainBank dataset. Of these, 1,507 of the genes were upregulated and 783 were downregulated in cases (Figure 1A, 1B). None of the 1000 random permutations produced more differentially expressed genes than the actual differential expression analysis, thus confirming the significance of these results. In the vast majority of the permutations, there were no differentially expressed genes these results. In the vast majority of the permutations, there were no differentially expressed genes (with adjusted p-value <0.05), with the number of significant genes across permutations averaging 4.5.

Figure 1. A) KCL BrainBank and C) TargetALS MA plots representing the distribution of log_2 fold change (logFC) across all expression levels; B) KCL BrainBank and D) TargetALS Volcano plots. Plot D has been cropped to exclude one point with extremely high log_2 fold change. Genes coloured red pass both the p-value and $logFC$ exclude one point with extremely high log2 fold change. Genes coloured red pass both the p-value and logFC fol
Excelse less color color color and significant and log FC folded by CC for change and log color color in the p thresholds. Grey genes are not significant, green genes only pass the logFC threshold, and blue genes only pass the logFC threshold. E) Numbers of differentially expressed genes in the two datasets.

TargetALS

A total of 402 genes were differentially expressed, with an adjusted p-value of <0.05, in the
TargetALS dataset. Of these, 250 of these genes were downregulated and 152 were upregulated in cases (Figure 1C, 1D). When performing random permutations, 9 (0.9%) produced as many or more differentially expressed genes as the actual differential expression analysis. In most of the differentially expressed genes as the actual differential expressed genes (with adjusted a velocid O OF). permutations, there were no differentially expressed genes (with adjusted p-value <0.05), with an average of 28 significantly expressed genes across permutations.

Shared Differentially Expressed Genes

l We found 44 genes significant in both datasets with an adjusted p-value of solos. All of these genes
had a concerdent direction of requision in both detects: 20 concerned acurerary leted and 15 had a concordant direction of regulation in both datasets; 29 genes were downregulated and 15
were upregulated (Figure 1E). To estimate the significance of this intersection between differentially expressed genes in the two datasets, we performed a hypergeometric test, using 41,709 as the expressed genes in the two datasets, we performed a hypergeometric test, using ϵ , ϵ and ϵ as the two datasets ϵ number of background genes. The p-value obtained was < 1.2e-05. Genes that were significant in both datasets are listed in Table 2.

j Table 2. Genes significantly differentially expressed in both datasets. Red: Upregulated; Blue: Downregulated' LogFC: Log2 of Fold Change

Enrichment Analyses

To compensate for the different numbers of differentially expressed genes in the two datasets when
using 0.05 as the corrected p-value threshold (2,290 genes in KCL BrainBank and 402 in TargetALS), we applied an additional threshold of logFC > 0.2 to the KCL BrainBank dataset. This yielded differential expression for 1,013 genes, which were uploaded to MetaCore for enrichment analysis along with the 402 differentially expressed genes in TargetALS. We performed analyses using MetaCore Pathway Maps, Process Networks, Disease Networks and GO processes. Supplementary MetaCore Pathway Maps, Process Networks, Disease Networks and GO processes. Supplementary Tables 2 and 3 list all enrichments with their p-value, false FDR adjusted p-value, and the genes from each dataset contributing to each enrichment.

Process Networks: neuropeptide signalling is altered in ALS in both datasets

Figures 2A and 2B display the most significant MetaCore Process Networks identified in the two
datasets. Among the most significant processes in KCL BrainBank are several neurological-related processes (Transmission of nerve impulse, Neuropeptide signalling pathways and Development Neurogenesis Axonal guidance) and processes related to muscle contraction. The most significant process network in TargetALS is Signal Transduction Neuropeptide signalling pathways, which was the third most significant KCL BrainBank process network. In TargetALS, among the most enriched the third most significant most significant process network. In target as $t_{\rm B}$ among the most enriched by the mos networks (albeit not significant) are several processes related to inflammation (interferon signalling and NK cell cytotoxicity).

Figure 2. Enrichment analysis results in the two datasets. The ten most significant enrichments are shown,
sorted by adjusted p-value, or fewer if there are less than ten significant after multiple testing correction. A) KCL BrainBank MetaCore Process Networks; B) TargetALS MetaCore Process Networks; C) KCL BrainBank MetaCore Pathway Maps; D) TargetALS MetaCore Pathway Maps; E) KCL BrainBank Reactome; For clarity, in panel E, one of the two redundant enrichments was omitted (Respiratory electron transport, which is more generalised of the one included, Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins). F) TargetALS Reactome. Following pathway abbreviations/names have been introduced: PF: Protein Folding; NP: Neurophysiological process; ST: Signal transduction; CS: Cytoskeleton; MC: Muscle contraction; POMC, alpha-MSH, AGRP, food intake, energy exp in hypothalamus: POMC, alpha-MSH and AGRP in regulation of food intake and energy expenditure in obesity in hypothalamus; Regulation of mp, excitability of cortical pyramidal neurons: Regulation of intrinsic membrane properties and excitability of cortical pyramidal neurons; Respiratory ET, ATP synthesis by CC, heat production: Respiratory excitability of cortical pyramidal neurons; Respiratory ET, ATP synthesis by CC, heat production: Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.

Pathway Maps: KCL BrainBank is enriched for neurophysiological processes, oxidative stress and
signal transduction, Target ALS is for POMC processing

Figures 2C and 2D present the most significantly enriched pathway maps in the two datasets. Prominent themes in the KCL BrainBank enrichments were neurophysiological processes, oxidative stress and signal transduction. There were three significant TargetALS pathway maps; two related to stress and signal transduction. There were three significant TargetALS pathway maps; two related to pro-opiomelanocortin (POMC) processing and one to immune response. Interestingly, the most significant network in TargetALS, POMC processing (Figure 3), includes several agonists of MC4R which is significantly upregulated in both datasets.

Figure 3. Protein folding and maturation POMC processing pathway map from MetaCore. Blue barometers represent downregulated genes from the TargetALS dataset. The descriptions of what the other symbols represent are analished in Complementary Cause 1 represent are available in Supplementary Figure 1.

KCL BrainBank is enriched for nervous system-specific processes while TargetALS is for immunological processes

Enrichments for MetaCore *Diseases by Biomarkers*, GO Biological Processes and Reactome pathways
are concordant in the two datasets. The KCL dataset showed clear nervous system related enrichments. These included disease enrichments (Heredodegenerative diseases, Huntington's disease, Central Nervous System diseases among others), GO Processes relevant to nervous system development, and Reactome pathways related to the functioning of the nervous system, such as the transmission of chemical synapses. TargetALS was enriched for immune system related diseases and processes, including diseases connected with response to various viral infections, GO Processes processes, including diseases connected with response to various viral infections, GO Processes related to immune defence, and Reactome pathways pertaining to interferon signalling (Figures 2E and 2F).

Correlation of neuropeptides and receptors expression with ALS phenotypic attributes

As neuropeptide signalling was the only altered biological network in both datasets, and neuropeptides have been implicated with the ALS clinical phenotype14-16, we decided to test the correlation between the expression of neuropeptides and their receptors with age at onset and disease duration of the ALS patients in both datasets. Several neuropeptides and receptors were found to be significantly correlated with age at onset and disease duration in at least one dataset ϵ (Table 3). NPBWR1 was found to be significantly correlated with age at onset in both KCL BrainBank and TargetALS after multiple testing correction, whilst TAC3 was nominally significantly correlated
with age at onset in TargetALS and after multiple testing correction in KCL BrainBank. *GNRH1* and TACR1 were nominally significantly correlated with survival and SSTR1 with age at onset in both datasets. Interestingly all neuropeptides and receptors that were significantly correlated with the age of onset of ALS in at least one dataset had a negative coefficient. Figure 4A shows NPBWR1 age of onset of ALS in at least one dataset had a negative coefficient. Figure 4A shows NPBWR1 expression against age of onset. Complete results can be found in Supplementary Tables 4, 5, 6 and 7.

Table 3. Results of the correlation analysis between neuropeptides and receptors, and clinical features. Only
results that are significant after FDR correction in at least one dataset, or nominally significant in both are results that are significant after FDR correction in at least one dataset, or nominally significant in both are
disclosed Completion that are at locationship limitia anticartical that datastic are related in an areal th displayed. Correlations that are at least nominally significant in both datasets are coloured in green, and those that are also significant after FDR correction in one dataset are also in bold.

Figure 4: A) Correlation analysis between NPBWR1 gene expression and age of onset in KCL BrainBank and TargetALS. B) Screenshot from ALS Gene Expression Explorer showing expression of MC4R, which was significantly upregulated in both datasets.

Cell Type Composition

Cell type composition analysis is shown in *Figure 5*. There was a significantly smaller proportion of endothelial cells in cases compared to controls in both datasets (KCL BrainBank: $F = 8.673$, p-value = 0.00369; TargetALS: F = 6.423, p-value = 0.0119). In the KCL dataset, cases also displayed higher 0.00369 ; TargetALS: F = 0.423, p-value = 0.0119; In the KCL dataset, cases also displayed higher 10.69 . neuronal cell (F = 25.256, p-value = 1.28 x 10-6) and lower oligodendrocyte levels (F = 13.633, p-value $= 0.000301$) whereas, in TargetALS, astrocytes were more prevalent amongst cases (F = 5.466, pvalue = 0.0203). The full results are available in Supplementary Table 8.

Figure 5. Case-control cell composition analysis in KCL BrainBank (left panel) and TargetALS (right panel), using
singular decomposition values generated by the BRETIGEA program for six cell types: A) Astrocytes, B) Endothelial Cells, C) Microglia, D) Neurons, E) Oligodendrocytes, F) Oligodendrocyte Progenitor Cells. Significance was assessed using one-way ANOVA. ns = non-significant, ns = non-significant, $* < 0.05$, $** < 0.01$, S_{S} significance was assessed using one-way ANOVA. ns = non-significant, ns = non-significant, * ~ 0.01 , * ~ 0.01 , $\sim 0.$ ** 0.001. Results were corrected for age and sex. Significance was assessed using one-way ANOVA. Results in age and sex. Significance was assessed using one-way ANOVA. Results were corrected for age and sex. Controls are in red and cases in green.

ALS Gene Expression Explorer

The ALS Gene Expression Explorer web application (https://alsgeexplorer.er.kcl.ac.uk) enables users
to explore and compare the expression levels for specific genes in ALS cases and controls in the two to explore and compare the expression levels for specific genes in ALS cases and controls in the two distributions of θ datasets. Figure 4B displays an example gene (MC4R) which is differentially expressed in both datasets.

l **Discussion**

By leveraging motor cortex expression data from two independent large datasets (a total of 224 ALS
cases and 79 controls), we reported ALS gene expression profiles that indicate the involvement of various biological processes in the pathology of ALS. We also identified genes in the neuropeptide signalling pathway that showed potential as biomarkers of ALS onset and progression. Differential expression analysis identified 2,290 and 402 differentially expressed genes in KCL BrainBank and TargetALS cases, respectively. Synapse-related processes, such as GABAergic neurotransmission, TargetALS cases, respectively. Synapse-related processes, such as GABAergic neurotransmission, including calcium-mediated signalling and postsynaptic signalling were significantly enriched in KCL BrainBank,

interferon signalling and NK cell neurotoxicity. This is most likely a product of the molecular
heterogeneity of ALS, as these two profiles reflect previously hypothesised mechanisms of ALS
pathogenesis and correspond to heterogeneity of ALS, as these two profiles reflect previously hypothesised mechanisms of ALS
pathogenesis and correspond to the predominant cell types identified in these datasets (neuronal
cells in KCL BrainBank and ast pathogenesis and correspond to the predominant cell types identified in these datasets (neuronal
cells in KCL BrainBank and astrocytes in TargetALS). Changes in the excitability patterns of GABAergic
interneurons influenc cells in KCL BrainBank and astrocytes in TargetALS). Changes in the excitability patterns of GABAergic
interneurons influence alterations in motor correx circuitry, which has been proposed as a possible
trigger for the sp interneurons influence alterations in motor cortex circuitry, which has been proposed as a possible
trigger for the spread of ALS pathology^{17,18}. Previous work has also implicated NK cells, which secrete
interferon-y an interneurons in the spread of ALS pathology^{17,18}. Previous work has also implicated NK cells, which secrete
interferon-y and are upregulated in the motor cortex and spinal cord of ALS patients^{19,20} as being
modulators

trigger for the spread of ALS pathology^{*/10}. Previous work has also implicated NK cells, which secrete interferon-γ and are upregulated in the motor cortex and spinal cord of ALS patients^{19,20} as being modulators of m interferon-γ and are upregulated in the motor cortex and spinal cord of ALS patients^{29,20} as being
modulators of motor neuron degeneration²¹, with interferon signalling pathways being upregulated
in spinal cord astrocy modulators of motor neuron degeneration⁴⁴, with interferon signalling pathways being upregulated
in spinal cord astrocytes in a *SOD1* ALS mouse model²².
Despite the diversity in the KCL BrainBank and TargetALS gene ex in spinal cord astrocytes in a *SOD1* ALS mouse model²².
Despite the diversity in the KCL BrainBank and TargetAl
signalling pathway was enriched in both datasets, whi
pathogenesis. The KCL BrainBank and TargetALS da
diff]
}
} } }
} signalling pathway was enriched in both datasets, which suggests that this is a key feature of ALS
pathogenesis. The KCL BrainBank and TargetALS datasets exhibited both unique and shared
differential expression of several pathogenesis. The KCL BrainBank and TargetALS datasets exhibited both unique and shared differential expression of several neuropeptide ligands and receptors. One gene, melanocortin receptor 4 (*MC4R*), was significantly differential expression of several neuropeptide ligands and receptors. One gene, melanocortin receptor 4 (*MC4R*), was significantly upregulated in both datasets. The role of the melanocortin system in ALS has largely bee receptor 4 (*MC4R*), was significantly upregulated in both datasets. The role of the melanocortin
system in ALS has largely been overlooked, despite *MC4R* activation inducing hypermetabolism,
increased energy expenditure receptor 4 (MC4R), was significantly upregulated in both datasets. The role of the includiocleantly system in ALS has largely been overlooked, despite *MC4R* activation inducing hypermetabolism, increased energy expenditu system in ALS has largely been overlooked, despite MC4R activation madeing hypermetabolism,
increased energy expenditure and cachexia; three processes associated with increased lower motor
neuron weakness and poor prognos neuron weakness and poor prognosis in ALS patients²³⁻²⁷. Furthermore, *MC4R*-mediated signalling in
the motor cortex also enhances the activity of sympathetic preganglionic neurons in the spinal cord,
which modulates ske which modulates skeletal muscle contraction^{28,29}, and rare (MAF <0.01) disruptive and damaging
missense variants in *MCAR* might increase the risk of ALS (Beta = 2.15 SE = 1.52, *p*-value = 0.037,
http://databrowser.pro

which modulates skeletal muscle contraction²⁰²², and rare (MAF <0.01) disruptive and damaging
missense variants in *MCAR* might increase the risk of ALS (Beta = 2.15 SE = 1.52, *p*-value = 0.037,
http://databrowser.proj missense variants in Me4R might increase the risk of ALS (Beta = 2.15 SE = 1.52, p-value = 0.037, http://databrowser.projectmine.com). Therefore, we suggest further investigation on MC4R as a potential candidate target ge meth.*f*/databrowser.projectmine.com). Therefore, we suggest further investigation on MC4R as a potential candidate target gene for future biomarker and screening studies.
Several *MC4R* agonists are involved in the trans-Several *MC4R* agonists are involved in the trans-Golgi network protein
pathway, which was the most significantly downregulated pathway in Tar
controlled by the *MC4R* ligand pro-opiomelanocortin (*POMC*), which acts as
t ミドハル betrial MC4R agonists are involved in the trans-Solgi network protein folding and maturation
pathway, which was the most significantly downregulated pathway in TargetALS. This pathway is
controlled by the MC4R ligand propathwall by the *MC4R* ligand pro-opiomelanocortin (*POMC*), which acts as a precursor peptide for
the *MC4R* agonists³⁰. Hence, aberrant protein degradation linked to both neuropeptide signalling
dysregulation and endo controlled by the MC4R ligand pro-ophomelanocortin (POMC), which acts as a precursor peptide for
the MC4R agonists³⁰. Hence, aberrant protein degradation linked to both neuropeptide signalling
dysregulation and endoplas the *MC4R* agonists³⁰. Hence, aberrant protein degradation linked to both neuropeptide signalling
dysregulation and endoplasmic reticulum associated stress could be a triggering event for ALS
pathogenesis. We observed r pathogenesis. We observed reduced expression of *POMC* in TargetALS (LogFC = -1.12, adjusted p-
value = 3.6E-05), which would undoubtedly affect the processing of several peptides reliant on
POMC cleavage in this pathwa pathogenesis. We observed reduced expression of PoMC in TargetALS (LogFC = 1.12, adjusted p-
value = 3.6E-05), which would undoubtedly affect the processing of several peptides reliant on
POMC cleavage in this pathway (*POMC* cleavage in this pathway (*6-endorphin*, $\mathbb{B}\text{-}MSH$, *6-MSH*). Their expression is linked to anti-
inflammatory processes in neurodegenerative diseases. For instance, *6-endorphin*, which normally
reduces the pr POME cleavage in this pathway (β-endorphin, E MOH, 8 MOH). Their expression is linked to anti-
inflammatory processes in neurodegenerative diseases. For instance, *β-endorphin*, which normally
reduces the production of p inflammatory processes in neurodegenerative diseases. For instance, *o-endorpmin*, which normally reduces the production of pro-inflammatory cytokines such as *interferon-y*, *IL-18* and *IL-2³¹* is found at lower leve reduces the production of pro-inflammatory cytokines such as *interferon-γ*, *IL-1*B and *IL-2* is found
at lower levels in the cerebrospinal fluid of Alzheimer's disease patients³². Similarly, both **D-***MSH* and
6-MSH at lower levels in the cerebrospinal fluid of Alzheimer's disease patients²². Similarly, both $\mathbb{E}I$ -*MSH* and θ -*MSH* are cytokine antagonists that protect against excitotoxic and apoptotic signalling effects in P *Barkinson's* and Alzheimer's disease models^{33,34}; actions that are also perturbed in ALS as evidenced
by similarly enriched pathways in this study. Therefore, the effects that *MCAR-POMC* signalling has
on inflammatory

Parkinson's and Alzheimer's disease models²⁰²⁴; actions that are also perturbed in ALS as evidenced
by similarly enriched pathways in this study. Therefore, the effects that *MC4R-POMC* signalling has
on inflammatory pro by similarly enticled pathways in this study. Therefore, the effects that MC4R-POMC signaling has
on inflammatory processes could also explain the significant enrichment of immune-related
processes observed in the TargetAL processes observed in the TargetALS dataset.
To further investigate how neuropeptide signalling affects clinical phenotype, we performed a
correlation analysis of neuropeptides and their receptors (102 neurotransmitters a Francesses and the TargetALS dataset.
To further investigate how neuropeptide si
correlation analysis of neuropeptides and t
present in KCL BrainBank and 111 in TargetA
receptors significantly correlated with the age of on ך
נו ז
t correlation analysis of neuropeptides and their receptors (102 neurotransmitters and attributes
present in KCL BrainBank and 111 in TargetALS) with clinical attributes. Several neuropeptides and
receptors significantly co present in KCL BrainBank and 111 in TargetALS) with clinical attributes. Several neuropeptides and
receptors significantly correlated with age of onset and survival in both datasets. *NPBWR1* was
significantly correlated preceptors significantly correlated with age of onset and survival in both datasets. *NPBWR1* was significantly correlated with the age of onset after multiple testing correction in both datasets (KCL BrainBank $r = -0.34$, receptors significantly correlated with age of onset and survival in both datasets. *NP bWH1* was
significantly correlated with the age of onset after multiple testing correction in both datasets (KCL
BrainBank $r = -0.34$, BrainBank $r = -0.34$, adjusted p-value = 0.019; TargetALS $r = -0.25$, adjusted p-value = 0.02).
Interestingly, *NPBWR1* is expressed by GABAergic interneurons and when activated, can dampen
their inhibitory effects³⁵. The BrainBank $r = 0.34$, adjusted p-value = 0.013, TargetALS $r = 0.25$, adjusted p-value = 0.02).
Interestingly, *NPBWR1* is expressed by GABAergic interneurons and when activated, can dampen
their inhibitory effects³⁵. The Interestingly, *NPBWR1* is expressed by GABAergic interneurons and when activated, can dampent
their inhibitory effects³⁵. Therefore, increased *NPBWR1* expression could have a greater impact on
the aforementioned altera their inhibitory effects³³. Therefore, increased *NPBWR1* expression could have a greater impact on
the aforementioned alterations in motor cortex circuitry, which would corroborate with the earlier
14 the aforemention alterations in motor cortex corresponding corresponding corresponding corresponding \mathcal{L}

age of onset in patients with higher *NPBWA1* levels. Excession of the somatostatine receptor *SSTR1*, which also resides on inhibitory GABAergic interneurons³⁶, was nominally negatively correlated with age of onset in t receptor *SSTR1*, which also resides on inhibitory GABAergic interneurons²⁶, was nominally negatively correlated with age of onset in the KCL BrainBank. We also found a nominally significant correlation between *TACR1* a between *TACR1* and *GNRH1* levels and survival in both datasets. Both *TACR1* and *GNRH1* can
stimulate the production and release of arachidonic acid^{37,38}, a polyunsaturated fatty acid whose
levels can distinguish ALS between TACR1 and GWMT1 levels and survival in both datasets. Both TACR1 and GWMT1 can
stimulate the production and release of arachidonic acid^{37,38}, a polyunsaturated fatty acid whose
levels can distinguish ALS patients stimulate the production and release of arachidonic acid^{37,33}, a polyunsaturated fatty acid whose
levels can distinguish ALS patients from mimics and controls and positively correlates with disease
progression³⁹, with

progression³⁹, with higher levels also found in spinal cord motor neuron cultures⁴⁰. Therefore, the role of the neuropeptide signalling system on lipid metabolism and cortical signalling in ALS is warranted to assess For the neuropeptical system of the neuropeptical phenotype.
When reviewing the 44 differentially expressed genes which were shared in both datasets, we found
that many were involved in integral themes of ALS pathogenesis, When reviewing the 44 differentially expressed genes wh
that many were involved in integral themes of ALS
metabolism, mitochondrial energy homeostasis (SULT1A.
dysfunction (AQP1, APLNR, CA12, AGPT1, CST3)⁴⁴⁻⁴⁸. I
needed)
trcrcrc that many were involved in integral themes of ALS pathogenesis, such as carbohydrate/lipid
metabolism, mitochondrial energy homeostasis (*SULT1A1, IP6K3, CPT1A*)⁴¹⁻⁴³, and neurovascular unit
dysfunction (*AQP1, APLNR, CA*

metabolism, mitochondrial energy homeostasis $(SULT1A1, IP6K3, CPT1A)^{41-43}$, and neurovascular unit
dysfunction (*AQP1, APLNR, CA12, AGPT1, CST3*)⁴⁴⁻⁴⁸. Further investigations of these genes are
needed to determine if they a metabolism, mitochondrial energy homeostasis (SULT1A1, IP6K3, CPT1A)⁻¹⁻⁴, and neurovascular unit
dysfunction (AQP1, APLNR, CA12, AGPT1, CST3)⁴⁴⁻⁴⁸. Further investigations of these genes are
needed to determine if they dystanction (AQP1, APLNN, CA12, AGPP1, CST3)
needed to determine if they are the drivers of alter
Our study has some limitations which are prima
expression signatures in post-mortem tissue. Firs
survived the neurodegenerat Further investigations of these genes are
ations in these pathways in ALS.
arily linked to the fact that we identified gene
stly, as the cells we derive expression for have
we cannot infer if the changes we are observing
o needed to the fact that we see the differential to determine the drivers of alternative pathways inverse pathways of alternative expression signatures in post-mortem tissue. Firstly, as the cells we derive experiment in al くらこく ドート expression signatures in post-mortem tissue. Firstly, as the cells we derive expression for have
survived the neurodegenerative processes of ALS, we cannot infer if the changes we are observing
are causing or are a consequ survived the neurodegenerative processes of ALS, we cannot infer if the changes we are observing
are causing or are a consequence of the ALS phenotype. We do not have information on the staging
of ALS in these patients so sure causing or are a consequence of the ALS phenotype. We do not have information on the staging of ALS in these patients so cannot attribute the expression profiles to a certain point of ALS progression. Furthermore, the of ALS in these patients so cannot attribute the expression profiles to a certain point of ALS
progression. Furthermore, there were 5.7 times more differentially expressed genes in KCL
BrainBank than in TargetALS. Although progression. Furthermore, there were 5.7 times more differentially expressed genes in KCL
BrainBank than in TargetALS. Although this might be linked to the larger number of controls in the
KCL datasets (~3 times more than PrainBank than in TargetALS. Although this might be linked to the larger number of controls in the KCL datasets (~3 times more than in TargetALS), there could also be several external factors influencing these datasets, su

RCL datasets (~3 times more than in TargetALS), there could also be several external factors influencing these datasets, such as library preparation, RNA extraction, sample quality, and population variability in gene expre influencing these datasets, such as library preparation, RNA extraction, sample quality, and
population variability in gene expression.
In summary, we identified several key modulatory themes of ALS pathogenesis as well as population variability in gene expression.
In summary, we identified several key modulatory themes of ALS pathogenesis as well as identified
genes in the neuropeptide signalling pathway that showed potential as diagnostic population variability in gene expression.
In summary, we identified several key modulatory themes of ALS pathogenesis as well as identified
genes in the neuropeptide signalling pathway that showed potential as diagnostic |
|}
| genes in the neuropeptide signalling pathway that showed potential as diagnostic and prognostic
biomarkers. There is a great need for accurate biomarkers in ALS, particularly for biomarkers that
predict the age of onset. T biomarkers. There is a great need for accurate biomarkers in ALS, particularly for biomarkers that
predict the age of onset. These could be explored to inform the study of the pre-symptomatic stages
of ALS and support the

Ethics declaration

biomarkers. There is a great need for a great need for a form the study of the pre-symptomatic stages
of ALS and support the development of pre-symptomatic diagnostic approaches⁴⁹.
Ethics declaration
Post-mortem tissue predict and support the development of pre-symptomatic diagnostic approaches⁴⁹.
 Ethics declaration
 **Post-mortem tissue samples from King's College London were collected under the ethical approval of

the MRC London N** of ALS and support the development of pre-symptomatic diagnostic approaches"".
Ethics declaration
Post-mortem tissue samples from King's College London were collected under the t
the MRC London Neurodegenerative Diseases B Post-mortem tissue samples from king's college London were collected under the ethical approval of
the MRC London Neurodegenerative Diseases Brain Bank and under the regulations of the Human
Tissue Act UK 2014. All post-mo Tissue Act UK 2014. All post-mortem tissue was donated to the MRC London Neurodegenerative
Diseases Brain Bank under standard ethical and Human Tissue Act procedures, with informed
consent provided by the next of kin. Data

Diseases Brain Bank under standard ethical and Human Tissue Act procedures, with informed
consent provided by the next of kin. Data generated from this material were anonymized and
analysed on a high-performance computing consent provided by the next of kin. Data generated from this material were anonymized and
analysed on a high-performance computing cloud
(https://www.maudsleybrc.nihr.ac.uk/facilities/rosalind/) with data protection proto analysed on a high-performance computing cloud
(https://www.maudsleybrc.nihr.ac.uk/facilities/rosalind/) with data protection protocols in
accordance with Department of Health Policy (UK) and the security standards set by (https://www.maudsleybrc.nihr.ac.uk/facilities/ro.
accordance with Department of Health Policy (UK)
Data Guardian. Ethical approval to process and ana
College London was provided by a local ethics com
Neuroscience, King's (https://www.matcondance with Department of Health Policy (UK) and the security standards set by the National College London. Ethical approval to process and analyse *post-mortem* samples stored at King College London was Data Guardian. Ethical approval to process and analyse *post-mortem* samples stored at King's
College London was provided by a local ethics committee at the Institute of Psychiatry, Psycholog
Neuroscience, King's College L Data Guardian. Ethical approval to process and analyse *post-mortem* samples stored at King's
College London was provided by a local ethics committee at the Institute of Psychiatry, Psycho
Neuroscience, King's College Lond Neuroscience, King's College London, and the MRC London Neurodegenerative Diseases Brain Bank.
Neuroscience, King's College London, and the MRC London Neurodegenerative Diseases Brain Bank.
15 15

Data availability

 raw RNAseq data from TargetALS samples can be requested by emailing c<u>end help@nygenome.org</u>
Results for individual genes can be visually explored at <u>https://alsgeexplorer.er.kcl.ac.uk/</u>. All data
analysis scripts used in results for individual genes can be visually explored at <u>https://alsgeexplorer.er.kcl.ac.uk/</u>. All data
analysis scripts used in this study are available at <u>https://github.com/rkabiljo/RNASeq Genes ERVs</u>
and <u>https://git</u> Results for individual general data that the sum of the visual general explormation of the state can be visually computed at the state

Acknowledgements

and <u>https://github.com/rkabiljo/DifferentialExpression Genes</u>
and <u>https://github.com/rkabiljo/DifferentialExpression Genes</u>
Acknowledgements
The TargetALS Human Postmortem Tissue Core, New York Genome Center for Genomics and <u>maging and hereing manipy substantine . The Target ALS</u>
The Target ALS Human Postmortem Tissue Core, New York Geno
Neurodegenerative Disease, the Amyotrophic Lateral Sclerosis A
Human post-mortem tissue was obtained f

Neurodegenerative Disease, the Amyotrophic Lateral Sclerosis Association and the Tow Fou
Human post-mortem tissue was obtained from the Medical Research Council London
Neurodegenerative Diseases Brain Bank (King's College Neurodegenerative Disease, Microna, Jerephic Disease, the Medical Research Council London
Neurodegenerative Diseases Brain Bank (King's College London). The London Neurodegenerative
Diseases Brain Bank at KCL has received

Neurodegenerative Diseases Brain Bank (King's College London). The London Neurod
Diseases Brain Bank at KCL has received funding from the MRC and through the Brains
Research project (jointly funded by Alzheimer's Society a Diseases Brain Bank at KCL has received funding from the MRC and through the Brains for Dement
Research project (jointly funded by Alzheimer's Society and Alzheimer's Research UK)'.
This work was carried out on King's Coll Research project (jointly funded by Alzheimer's Society and Alzheimer's Research UK)'.
This work was carried out on King's College HPC Create: King's College London. (2022). King's
Computational Research, Engineering and T Research project (jointly funded by Alzheimer's Society and Alzheimer's Research UK)'.
This work was carried out on King's College HPC Create: King's College London. (2022).
Computational Research, Engineering and Technolo This work was carried out on King's College HPC Create: King's College London. (2022). King's Computational Research, Engineering and Technology Environment (CREATE). Retrieved Marc
2022, from <u>https://doi.org/10.18742/rnv</u> 2022, from https://doi.org/10.18742/rnvf-m076, and on the Pawsey Supercomputing Research
Centre with funding from the Australian Government and the Government of Western Australia.
RK is funded by MND Scotland, grant numbe

2022, Centre with funding from the Australian Government and the Government of Western Australia
2022, FR is funded by MND Scotland, grant number RE14937.
2023. HM is funded by GlaxoSmithKline and the KCL funded centre for

RK is funded by MND Scotland, grant number RE14937.
HM is funded by GlaxoSmithKline and the KCL funded centre for Doctoral Training (CDT) in Data-
Driven Health.
GH is funded by Perron Institute for Neurological and Transl MAT TAMELARY (MAT SCONDR), grammanned MELASON
RM is funded by GlaxoSmithKline and the KCL funded ce
Driven Health.
GH is funded by Perron Institute for Neurological and Tr
centre for Doctoral Training (CDT) in Data-Driven Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government
Health and Social Care Directorates, Health and Social Care Research and Development Division **GH** is funded by
Centre for Doct
Biomedical Res
London, Londo
Council, Engine
Department of
Health and Soc centre for Doctoral Training (CDT) in Data-Driven Health.RJBD is supported by the following: (1)
Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's Cc
London, London, UK; (2) Health Dat Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College
London, London, UK; (2) Health Data Research UK, which is funded by the UK Medical Research
Council, Engineering and Physical Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College
London, London, UK; (2) Health Data Research UK, which is funded by the UK Medical Research
Council, Engineering and Physical Louncil, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottis Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government
Health and Social Care Directorates, Health and Social Care Research and Development Division
(Welsh Government), Public Hea Pealth and Social Care Directorates, Health and Social Care Research and Development Division
(Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and
Wellcome Trust; (3) The BigData@Heart (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and
Wellcome Trust; (3) The BigData@Heart Consortium, funded by the Innovative Medicines Initiat
Joint Undertaking under grant agreement Wellcome Trust; (3) The BigData@Heart Consortium, funded by the Innovative Medicines Inity Undertaking under grant agreement No. 116074. This Joint Undertaking receives supporthe European Union's Horizon 2020 research and Voint Undertaking under grant agreement No. 116074. This Joint Undertaking receives support from
the European Union's Horizon 2020 research and innovation programme and EFPIA; it is chaired by
DE Grobbee and SD Anker, part Fire European Union's Horizon 2020 research and innovation programme and EFPIA; it is chaired by
DE Grobbee and SD Anker, partnering with 20 academic and industry partners and ESC; (4) the
National Institute for Health Res the European Union's Horizon 2020 research and innovation programme and EFPIA; it is chaired by
DE Grobbee and SD Anker, partnering with 20 academic and industry partners and ESC; (4) the
National Institute for Health Rese National Institute for Health Research University College London Hospitals Biomedical Research
Centre; (5) the National Institute for Health Research (NIHR) Biomedical Research Centre at Sou
London and Maudsley NHS Foundat Centre; (5) the National Institute for Health Research (NIHR) Biomedical Research Centre at Sout
London and Maudsley NHS Foundation Trust and King's College London; (6) the UK Research and
Innovation London Medical Imaging London and Maudsley NHS Foundation Trust and King's College London; (6) the UK Research and
Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare; (7)
the National Institute for Heal London and Maudsley NHS Foundation Trust and King's College London; (6) the UK Research and
Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare; (7
the National Institute for Healt the National Institute for Health Research (NIHR) Applied Research Collaboration South London
(NIHR ARC South London) at King's College Hospital NHS Foundation Trust.
AAC is an NIHR Senior Investigator (NIHR202421). This r

(NIHR ARC South London) at King's College Hospital NHS Foundation Trust.
AAC is an NIHR Senior Investigator (NIHR202421). This research is part an EU Joint Programme -
Neurodegenerative Disease Research (JPND) project. The (NIHR ARC South London) at King's College Hospital NHS Foundation Trust.
AAC is an NIHR Senior Investigator (NIHR202421). This research is part an E
Neurodegenerative Disease Research (JPND) project. The project is support Neurodegenerative Disease Research (JPND) project. The project is supported through the follow
16 $\n 16\n \n 16\n$

Research Council and the Motor Neurone Disease Association. Funding for open access charge:
Al is funded by the Motor Neurone Disease Association. This study represents independent researtly funded by the National Institut Al is funded by the Motor Neurone Disease Association. This study represents independent research
partly funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at
South London and Maudsley N partly funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at
South London and Maudsley NHS Foundation Trust and King's College London. BA acknowledges
funding through a Pre-doctoral Fell South London and Maudsley NHS Foundation Trust and King's College London. BA acknowledges funding through a Pre-doctoral Fellowship from the NIHR (NIHR301067). We acknowledge use of tresearch computing facility at King's C South London and Maudsley NHS Foundation Trust and King's College London. BA acknowledges
funding through a Pre-doctoral Fellowship from the NIHR (NIHR301067). We acknowledge use of
research computing facility at King's Co research computing facility at King's College London, Rosalind (https://rosalind.kcl.ac.uk), which is delivered in partnership with the National Institute for Health Research (NIHR) Biomedical Research Centres at South Lon research computing facility at King's College London, Rosalind (https://rosalind.kcl.ac.uk), which is
delivered in partnership with the National Institute for Health Research (NIHR) Biomedical Researc
Centres at South Lond Centres at South London & Maudsley and Guy's & St. Thomas' NHS Foundation Trusts and part-
funded by capital equipment grants from the Maudsley Charity (award 980) and Guy's and St
Thomas' Charity (TR130505). The views exp Centres at South London & Maudsley and Guy's & St. Thomas' NHS Foundation Trusts and part-
funded by capital equipment grants from the Maudsley Charity (award 980) and Guy's and St
Thomas' Charity (TR130505). The views exp funded by capital equipment grants from the Maudsley Charity (award 980) and Guy's and St
Thomas' Charity (TR130505). The views expressed are those of the author(s) and not necessai
those of the NHS, the NIHR, King's Colle

References

Thomas' Charity (TR130505). The views expressed are those of the author(s) and not necessarily
those of the NHS, the NIHR, King's College London, or the Department of Health and Social Care.
References
1. Julien JP. Amyotr those of the NHS, the NIHR, King's College London, or the Department of Health and Social Care.

References

1. Julien JP. Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded. C

Feb 23 2001;104(4):581-9 1. Julien JP. Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded. *Cell*. Feb 23 2001;104(4):581-91. doi:10.1016/s0092-8674(01)00244-6

2. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. *N Engl J Med*. May 31 2001;344(22):1688-700. doi:10.1056/NEJM200105313442207

3. Wang XS, Simmons Z, Liu W, Boyer PJ, Connor JR. Differential expression of genes in amyotrophic lateral sclerosis revealed by profiling the post mortem cortex. *Amyotroph Lateral Scler*. Dec 2006;7(4):201-10. doi:10.1080/17482960600947689

4. Dols-Icardo O, Montal V, Sirisi S, et al. Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. *Neurol Neuroimmunol Neuroinflamm*. Sep 2020;7(5)doi:10.1212/NXI.0000000000000829

5. Iacoangeli A, Fogh I, Selvackadunco S, et al. SCFD1 expression quantitative trait loci in amyotrophic lateral sclerosis are differentially expressed. *Brain Commun*. 2021;3(4):fcab236. doi:10.1093/braincomms/fcab236

6. Jones AR, Iacoangeli A, Adey BN, et al. A HML6 endogenous retrovirus on chromosome 3 is upregulated in amyotrophic lateral sclerosis motor cortex. *Sci Rep*. Jul 12 2021;11(1):14283. doi:10.1038/s41598-021-93742-3

7. Brian B. BBMap: A Fast, Accurate, Splice-Aware Aligner. *Lawrence Berkeley National Lab (LBNL), Berkeley, CA (United States)*. 2014;

8. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*. Jan 1 2013;29(1):15-21. doi:10.1093/bioinformatics/bts635

9. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with highthroughput sequencing data. *Bioinformatics*. Jan 15 2015;31(2):166-9. doi:10.1093/bioinformatics/btu638

10. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol*. 2014;15(12):550. doi:10.1186/s13059-014- 0550-8

11. Raudvere U, Kolberg L, Kuzmin I, et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). *Nucleic Acids Res*. Jul 2 2019;47(W1):W191-W198. doi:10.1093/nar/gkz369

12. Gillespie M, Jassal B, Stephan R, et al. The reactome pathway knowledgebase 2022. *Nucleic Acids Res*. Jan 7 2022;50(D1):D687-D692. doi:10.1093/nar/gkab1028

13. McKenzie AT, Wang M, Hauberg ME, et al. Brain Cell Type Specific Gene Expression and Co-expression Network Architectures. *Sci Rep*. Jun 11 2018;8(1):8868. doi:10.1038/s41598-018-27293-5

14. Ahmed RM, Phan K, Highton-Williamson E, et al. Eating peptides: biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia. *Ann Clin Transl Neurol*. Mar 2019;6(3):486-495. doi:10.1002/acn3.721

15. Clark CM, Clark RM, Hoyle JA, Dickson TC. Pathogenic or protective? Neuropeptide Y in amyotrophic lateral sclerosis. *J Neurochem*. Feb 2021;156(3):273-289. doi:10.1111/jnc.15125

16. Zuccaro E, Piol D, Basso M, Pennuto M. Motor Neuron Diseases and Neuroprotective Peptides: A Closer Look to Neurons. *Front Aging Neurosci*. 2021;13:723871. doi:10.3389/fnagi.2021.723871

17. Eisen A, Braak H, Del Tredici K, Lemon R, Ludolph AC, Kiernan MC. Cortical influences drive amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry*. Nov 2017;88(11):917-924. doi:10.1136/jnnp-2017-315573

18. Scekic-Zahirovic J, Fischer M, Stuart-Lopez G, et al. Evidence that corticofugal propagation of ALS pathology is not mediated by prion-like mechanism. *Prog Neurobiol*. May 2021;200:101972. doi:10.1016/j.pneurobio.2020.101972

19. Gustafson MP, Staff NP, Bornschlegl S, et al. Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis. *PLoS One*. 2017;12(7):e0182002. doi:10.1371/journal.pone.0182002

20. Murdock BJ, Zhou T, Kashlan SR, Little RJ, Goutman SA, Feldman EL. Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression. *JAMA Neurol*. Dec 1 2017;74(12):1446-1454. doi:10.1001/jamaneurol.2017.2255

21. Garofalo S, Cocozza G, Porzia A, et al. Natural killer cells modulate motor neuronimmune cell cross talk in models of Amyotrophic Lateral Sclerosis. *Nat Commun*. Apr 14 2020;11(1):1773. doi:10.1038/s41467-020-15644-8

22. Wang R, Yang B, Zhang D. Activation of interferon signaling pathways in spinal cord astrocytes from an ALS mouse model. *Glia*. Jun 2011;59(6):946-58. doi:10.1002/glia.21167

23. Holm T, Maier A, Wicks P, et al. Severe loss of appetite in amyotrophic lateral sclerosis patients: online self-assessment study. *Interact J Med Res*. Apr 17 2013;2(1):e8. doi:10.2196/ijmr.2463

24. Jesus P, Fayemendy P, Nicol M, et al. Hypermetabolism is a deleterious prognostic factor in patients with amyotrophic lateral sclerosis. *Eur J Neurol*. Jan 2018;25(1):97-104. doi:10.1111/ene.13468

25. Kasarskis EJ, Mendiondo MS, Matthews DE, et al. Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis. *Am J Clin Nutr*. Apr 2014;99(4):792-803. doi:10.3945/ajcn.113.069997

26. Kurihara M, Bamba S, Yasuhara S, et al. Factors Affecting Energy Metabolism and Prognosis in Patients with Amyotrophic Lateral Sclerosis. *Ann Nutr Metab*. 2021;77(4):236- 243. doi:10.1159/000518908

27. Steyn FJ, Ioannides ZA, van Eijk RPA, et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. *J Neurol Neurosurg Psychiatry*. Oct 2018;89(10):1016-1023. doi:10.1136/jnnp-2017-317887

28. Sohn JW, Harris LE, Berglund ED, et al. Melanocortin 4 receptors reciprocally regulate sympathetic and parasympathetic preganglionic neurons. *Cell*. Jan 31 2013;152(3):612-9. doi:10.1016/j.cell.2012.12.022

29. Ye DW, Liu C, Liu TT, Tian XB, Xiang HB. Motor cortex-periaqueductal gray-spinal cord neuronal circuitry may involve in modulation of nociception: a virally mediated

transsynaptic tracing study in spinally transected transgenic mouse model. *PLoS One*. 2014;9(2):e89486. doi:10.1371/journal.pone.0089486

30. Harno E, Gali Ramamoorthy T, Coll AP, White A. POMC: The Physiological Power of Hormone Processing. *Physiol Rev*. Oct 1 2018;98(4):2381-2430.

doi:10.1152/physrev.00024.2017

31. Pilozzi A, Carro C, Huang X. Roles of beta-Endorphin in Stress, Behavior, Neuroinflammation, and Brain Energy Metabolism. *Int J Mol Sci*. Dec 30 2020;22(1)doi:10.3390/ijms22010338

32. Jolkkonen JT, Soininen HS, Riekkinen PJ. beta-Endorphin-like immunoreactivity in cerebrospinal fluid of patients with Alzheimer's disease and Parkinson's disease. *J Neurol Sci*. Feb 1987;77(2-3):153-9. doi:10.1016/0022-510x(87)90118-3

33. Giuliani D, Neri L, Canalini F, et al. NDP-alpha-MSH induces intense neurogenesis and cognitive recovery in Alzheimer transgenic mice through activation of melanocortin MC4 receptors. *Mol Cell Neurosci*. Jul 2015;67:13-21. doi:10.1016/j.mcn.2015.05.004

34. Peng T, Wang J, Lu J, Lu H, Teng J, Jia Y. Neuroprotective effects of alphamelanocyte-stimulating hormone against the neurotoxicity of 1-methyl-4-phenylpyridinium. *IUBMB Life*. May 2017;69(5):315-320. doi:10.1002/iub.1385

35. Chottova Dvorakova M. Distribution and Function of Neuropeptides W/B Signaling System. *Front Physiol*. 2018;9:981. doi:10.3389/fphys.2018.00981

36. Lukomska A, Dobrzanski G, Liguz-Lecznar M, Kossut M. Somatostatin receptors (SSTR1-5) on inhibitory interneurons in the barrel cortex. *Brain Struct Funct*. Jan 2020;225(1):387-401. doi:10.1007/s00429-019-02011-7

37. Naor Z, Catt KJ. Mechanism of action of gonadotropin-releasing hormone. Involvement of phospholipid turnover in luteinizing hormone release. *J Biol Chem*. Mar 10 1981;256(5):2226-9.

38. Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. *Physiol Rev*. Jan 2014;94(1):265-301. doi:10.1152/physrev.00031.2013

39. Lawton KA, Brown MV, Alexander D, et al. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. *Amyotroph Lateral Scler Frontotemporal Degener*. Sep 2014;15(5-6):362-70. doi:10.3109/21678421.2014.908311

40. Lee H, Lee JJ, Park NY, et al. Multi-omic analysis of selectively vulnerable motor neuron subtypes implicates altered lipid metabolism in ALS. *Nat Neurosci*. Dec 2021;24(12):1673-1685. doi:10.1038/s41593-021-00944-z

41. Sidharthan NP, Minchin RF, Butcher NJ. Cytosolic sulfotransferase 1A3 is induced by dopamine and protects neuronal cells from dopamine toxicity: role of D1 receptor-Nmethyl-D-aspartate receptor coupling. *J Biol Chem*. Nov 29 2013;288(48):34364-74. doi:10.1074/jbc.M113.493239

42. Dato S, Crocco P, De Rango F, et al. IP6K3 and IPMK variations in LOAD and longevity: Evidence for a multifaceted signaling network at the crossroad between neurodegeneration and survival. *Mech Ageing Dev*. Apr 2021;195:111439. doi:10.1016/j.mad.2021.111439

43. Trabjerg MS, Andersen DC, Huntjens P, et al. Downregulating carnitine palmitoyl transferase 1 affects disease progression in the SOD1 G93A mouse model of ALS. *Commun Biol*. Apr 30 2021;4(1):509. doi:10.1038/s42003-021-02034-z

44. Bonomini F, Rezzani R. Aquaporin and blood brain barrier. *Curr Neuropharmacol*. Jun 2010;8(2):92-6. doi:10.2174/157015910791233132

45. Siddiqui MR, Mayanil CS, Kim KS, Tomita T. Angiopoietin-1 Regulates Brain Endothelial Permeability through PTPN-2 Mediated Tyrosine Dephosphorylation of Occludin. *PLoS One*. 2015;10(6):e0130857. doi:10.1371/journal.pone.0130857

46. Benndorf RA. Renal Biomarker and Angiostatic Mediator? Cystatin C as a Negative Regulator of Vascular Endothelial Cell Homeostasis and Angiogenesis. *J Am Heart Assoc*. Nov 6 2018;7(21):e010997. doi:10.1161/JAHA.118.010997

47. Hu G, Wang Z, Zhang R, Sun W, Chen X. The Role of Apelin/Apelin Receptor in Energy Metabolism and Water Homeostasis: A Comprehensive Narrative Review. *Front Physiol*. 2021;12:632886. doi:10.3389/fphys.2021.632886

48. Hosford PS, Wells JA, Nizari S, et al. CO(2) signaling mediates neurovascular coupling in the cerebral cortex. *Nat Commun*. Apr 19 2022;13(1):2125. doi:10.1038/s41467- 022-29622-9

49. Benatar M, Wuu J, McHutchison C, et al. Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. *Brain*. Mar 29 2022;145(1):27- 44. doi:10.1093/brain/awab404